56.40SEK+1.08%Mkt Cap: 759.79M SEKP/E: —Last update: 2026-06-01
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug c…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap759.79M SEK
Enterprise Value619.78M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-65.17M SEK
Revenue/Share—
Last Price56.40 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B9.10
EPS (TTM)-5.32
EPS (Forward)—
52W Range
43.2532% of range84.30
52W High84.30 SEK
52W Low43.25 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-61.87%
ROA-40.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-72.34M SEK
CapEx (TTM)—
FCF Margin—
FCF Yield-4.67%
Net Debt-131.93M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio2.23
Quick Ratio2.21
Book Value/Sh6.130 SEK
Cash/Share9.793 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.02M
Float11.23M
Insiders17.49%
Institutions33.77%
Technical
SMA 5052.72 (+7.0%)
SMA 20055.14 (+2.3%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)11.74K
Avg Vol (10d)12.74K
Technical Indicators
RSI (14)54.4
MACD0.3327
MACD Signal0.5462
MACD Hist.-0.2136
BB Upper58.52 SEK
BB Middle54.97 SEK
BB Lower51.42 SEK
BB Width12.90%
ATR (14)3.419 SEK
Vol Ratio (20d)0.76x